Fig. 6 | Nature Communications

Fig. 6

From: Tet1 and Tet2 maintain mesenchymal stem cell homeostasis via demethylation of the P2rX7 promoter

Fig. 6The alternative text for this image may have been generated using AI.

P2rX7 activation rescues impaired Tet DKO BMMSCs and osteopenia phenotype in Tet DKO mice. a The levels of miR-297a-5p, miR-297b-5p, and miR-297c-5p in control, Tet DKO BMMSCs, and P2rX7 CRISPR activation plasmid-treated Tet DKO BMMSCs. b Bradford assay showed the exosome secretion in control, Tet DKO BMMSCs, and P2rX7 CRISPR activation plasmid-treated Tet DKO BMMSCs. c Western blotting showed the expression of CD9 and CD81 in control, Tet DKO BMMSCs, and P2rX7 CRISPR activation plasmid-treated Tet DKO BMMSCs. d, e Mineralized nodule formation and the expression of Runx2, ALP, and OCN in control, Tet DKO BMMSCs, and P2rX7 CRISPR activation plasmid-treated Tet DKO BMMSCs, as assessed by alizarin red staining (d) and western blotting (e). f The expression of miR-297a-5p, miR-297b-5p, and miR-297c-5p in control, Tet DKO BMMSCs, and adeno-associated P2rX7 overexpression virus (P2rX7 AAV)-treated Tet DKO BMMSCs, as assessed by qPCR. g Bradford assay showed the exosome secretion level in control, Tet DKO BMMSCs, and P2rX7 AAV-treated BMMSCs. h Western blotting showed the expression of CD9 and CD81 in exosomes derived from control, Tet DKO BMMSCs, and P2rX7 AAV-treated BMMSCs. i Bone mineral density (BMD) of trabecular bone (TB) area in distal femurs of control, Tet DKO, and P2rX7 AAV-treated-mice, as assessed by micro-CT. j The cortical bone area (Ct.Ar) and cortical thickness (Ct.Th) of the femurs of control, Tet DKO, and P2rX7 AAV-treated-mice analyzed by micro-CT. k, l H&E staining showed the TB volume (yellow-circled area) of control, Tet DKO, and P2rX7 AAV-treated-mice. m The capacity of BMMSCs isolated from control, Tet DKO, and P2rX7 AAV-treated-mice to form mineralized nodules as assessed by alizarin red staining. n Western blotting analysis showed the expression levels of the osteogenic markers Runx2, ALP, and OCN in control, Tet DKO, and P2rX7 AAV-treated Tet DKO BMMSCs. The 8–10-week-old Tet1−/−Prx1creTet2fl/fl mice were used as Tet DKO mice in our experiments, and their littermates whose genetic status was Prx1cre were used as controls. *p < 0.05, **p < 0.01, ***p < 0.001 (mean ± SD). Scale bars, 400 μm (i, j), 1 mm (k). Results are from three independent experiments. p values were calculated using one-way ANOVA

Back to article page